PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting

Cited by (191)

Items 101–191 of 191

1. Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer
   Huang, Mengqiu, Chen, Lin, Ma, Xiaoyan, Xu, Houqiang · 2024 · Cancer Cell International
2. Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors
   Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal J. Lakhani, Hendrik‐Tobias Arkenau, Matthew D. Galsky, Emiliano Calvo, Vicente Baz, Víctor Moreno et al. · 2024 · Cancer Medicine
3. Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology
   Jessica A. Scarborough, Jacob G. Scott · 2021 · Seminars in Radiation Oncology
4. Defective DNA repair in hereditary ovarian cancers: Implications for therapy
   Brian T. Burgess, Jill Kolesar · 2018 · American Journal of Health-System Pharmacy
5. PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for
   Sara Parola, Christoph Oing, Pasquale Rescigno, Salvatore Feliciano, Francesca Carlino, Luca Pompella, Antonella Lucia Marretta, Irene De Santo, Martina Viggiani, Margherita Muratore et al. · 2024 · Frontiers in Genetics
6. Comprehensive genomic dependency landscape of a human colon cancer organoid
   Sanam Khalili, Atefeh Mohseninia, Changlong Liu, Carolyn E. Banister, Paige Heine, M. Khazan, Sidney E. Morrison, P. Gokare, G. Cowley, Barbara A. Weir et al. · 2025 · Communications Biology
7. BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery
   Oliver Trusler, Jacob Goodwin, Andrew L. Laslett · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
8. A Review of Current treatment for Triple-Negative Breast Cancer (TNBC)
   Wahyuni Wahyuni, Ajeng Diantini, Mohammad Ghozali, Idin Sahidin · 2022 · Research Journal of Pharmacy and Technology
9. WGS Data Collections: How Do Genomic Databases Transform Medicine?
   Zbigniew J. Król, Paula Dobosz, Antonina Ślubowska, Magdalena Mroczek · 2023 · International Journal of Molecular Sciences
10. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
    Song Mu, Chester Lin, Anna Skrzypczyk-Ostaszewicz, Iurie Bulat, Marina Maglakelidze, Viera Skarbová, Claudia Andreu‐Vieyra, Srikumar Sahasranaman · 2021 · Cancer Chemotherapy and Pharmacology
11. Targeting the Sodium–Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia
    Constanze Schneider, Hermes Spaink, Gabriela Alexe, Neekesh V. Dharia, Ashleigh Meyer, Lucy A. Merickel, Delan Khalid, Sebastian Scheich, Björn Häupl, Louis M. Staudt et al. · 2024 · Cancer Research
12. Olaparib: A tale of two dosage forms
    Trevor N. Christ · 2018 · Seminars in Oncology
13. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients
    Caitlin Phillips-Chavez, Michael Watson, Jermaine Ian George Coward, Janet Margaret Schloss · 2020 · European Journal of Clinical Pharmacology
14. Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants
    Katherine E. Zarn, Sierra A. Jaramillo, Anthony R. Zapata, Nathan E. Stone, Ashley N. Jones, Haley E. Nunnally, Erik W. Settles, Ken Ng, Paul Keim, Steen Knudsen et al. · 2022 · PLoS ONE
15. Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification
    Holly Tovey, Maggie C.U. Cheang · 2019 · Cancers
16. Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma
    Anna F. Piotrowski, Kent C. Shih, Pierre Giglio, Howard Colman, Patrick Yung Wen, Jian Li Campian, Nicholas Arthur Butowski, Timothy Francis Cloughesy, Zhaoyin Zhu, Vitaliy Gisin et al. · 2025 · Current Oncology
17. PARP10 is highly expressed and associated with inferior outcomes in acute myeloid leukemia
    Ling Wang, Chuang Jiang, Dandan Hu · 2023 · Aging
18. Exploring the endogenous potential of Hemidesmus indicus against breast cancer using in silico studies and quantification of 2-hydroxy-4-methoxy benzaldehyde through RP-HPLC
    Akash Anand Bansod, R. Gnanam, Bharathi Nathan, Rajamani Kandhasamy, P Meenakshisundaram, V P Santhanakrishnan · 2021 · 3 Biotech
19. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans
    Guettchina Telisnor, David L. DeRemer, Esther Frimpong, Edward Agyare, John M. Allen, Luisel J. Ricks‐Santi, Bo Han, Thomas J. George, Sherise Chantell Rogers · 2023 · Journal of the National Medical Association
20. Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical Implications
    Martin Kondža, Josipa Bukić, Ivan Ćavar, Biljana Tubić · 2025 · Drugs and Drug Candidates
21. Current and Future Trends in Neoadjuvant Immunotherapy for the Treatment of Triple-Negative Breast Cancer
    Ramon Andrade de Mello, Kátia Roque, Thaís Perez Vazquez · 2024 · Immunotherapy
22. Hemodynamic Considerations in the Pathophysiology of Peripheral Neuropathy
    Daryl Irving Smith, Hai Thanh Tran, Joseph W. Poku · 2018 · InTech eBooks
23. Circulating Tumor Cells and γH2AX As Biomarkers for Responsiveness to radium-223 in Advanced Prostate Cancer Patients
    Jonathan Alexander Chatzkel, Jesse Mocha, J. Joshua Smith, Junmin Zhou, Youngchul Kim, Ghassan E. El-Haddad, Jingsong Zhang · 2019 · Future Science OA
24. Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency
    Nabila Zaman, Atar Singh Kushwah, Anagha Badriprasad, Goutam Chakraborty · 2024 · International review of cytology
25. Clinical Impact of Somatic Genomic Testing on Breast Cancer Care
    Taha Khalid, Ramsey Cutress, Marcus Remer, Ellen Copson · 2024 · Clinical Oncology
26. Recent Progress in Poly(ADP–Ribose) Polymerase‐1 Inhibitors for Application in Cancer
    Anuradha Mehra, Shahnaz Islam, Rekha Sangwan · 2025 · ChemistrySelect
27. ATR Inhibition Synergizes With Alkylating PI Polyamide Targeting MYCN by Suppressing DNA Repair in MYCN ‐Amplified Neuroblastoma
    Xiaoyi Lai, Hiroyuki Yoda, Yuming Qiao, Yuki Kida, Keizo Takenaga, Yoshinao Shinozaki, Nobuko Koshikawa, Atsushi Takatori · 2025 · Cancer Science
28. Development and External Validation of a Novel Model for Predicting Postsurgical Recurrence and Overall Survival After Cytoreductive R0 Resection of Epithelial Ovarian Cancer
    Qiaqia Li, Yinghong Deng, Wei Wei, Fan Yang, An Lin, Desheng Yao, Xiaofeng Zhu, Jundong Li · 2022 · Frontiers in Oncology
29. [18F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology
    Honest Ndlovu, Ismaheel O. Lawal, Sipho Mdanda, Mankgopo Kgatle, Kgomotso M. G. Mokoala, Akram Al‐Ibraheem, Mike Machaba Sathekge · 2024 · Journal of Clinical Medicine
30. First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
    Federica Tomao, Serena Maria Boccia, Carolina Maria Sassu, Martina Chirra, Innocenza Palaia, Maria Cristina Petrella, Violante Di Donato, Nicoletta Colombo, Pierluigi Benedetti Panici · 2020 · Cancer Management and Research
31. Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer
    Sayed Reshad Ghafouri, Suvarna L Guvvala, Catherine Jones, Alexander V. Philipovskiy · 2022 · Journal of Investigative Medicine
32. Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data
    Reem D. Mahmood, Kathryn Graham, Jack Patrick Gleeson, Richard A Hubner, Juan W. Valle, Mairead Geraldine McNamara · 2023 · Immunotherapy
33. Cancer Prevention Clinical Trials: Advances and Challenges
    Elizabeth R. Francis, Dr. Farzeen Syed, Arun Rajan, Eva M. Szabo · 2026 · Cancers
34. International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review
    Vsevolod Borisovich Matveev, Oybek Khalmurzaev, О. I. Evsyukova · 2020 · Cancer Urology
35. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers
    Pengfei Du, Yao Long, Minhui Wang, Yunzhe Huang, Yaqin Wang, Xinyan Chen, Yuhong Lin, Jianbang Wu, Jie Shen, Yuanwei Jia · 2024 · Cancer Chemotherapy and Pharmacology
36. PARP1 in melanoma: Mechanistic insights and implications for basic and clinical research
    Andrea Marranci, Luisa Maresca, Samuele Lodovichi, Andrea Ghelli Luserna di Rorà, Barbara A. Stecca, Laura Poliseno · 2025 · Cancer Letters
37. In silico study reveals unconventional interactions between MDC1 of DDR and Beclin-1 of autophagy
    Kavya Ajit Pandya, Neeru Singh · 2022 · Molecular Diversity
38. Incorporating functional genomics into the pathology-supported genetic testing framework implemented in South Africa: A future view of precision medicine for breast carcinomas
    Claudia Christowitz, Daniel Wilhelm Olivier, Johann W. Schneider, Maritha J. Kotze, Anna‐Mart Engelbrecht · 2024 · Mutation Research/Reviews in Mutation Research
39. Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis
    Min Tang, Yue Wang, Pulin Li, Rui Han, Ran Wang · 2024 · Frontiers in Pharmacology
40. DNA damage targeted therapy for advanced breast cancer
    Vanessa Patel, Sandra Casimiro, Catarina Abreu, Tiago Barroso, Rita Sousa, Sofía Torres, Leonor Ribeiro, Gonçalo Nogueira-Costa, Helena Luna Pais, Conceição Pinto et al. · 2024 · Exploration of Targeted Anti-tumor Therapy
41. AmNA ‐Modified Antisense Oligonucleotide Targeting MCM8 as a Cancer‐Specific Chemosensitizer for Platinum Compounds
    Yuki Uchibori, Masaki Suekuni, Yuko Kokaji, Kazumasa Yoshida, Tohru Kiyono, Yuuya Kasahara, Masatoshi Fujita · 2025 · Cancer Science
42. Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out
    Danny Wilbie, Selma Eising, Vicky Amo-Addae, Johanna Walther, Esmeralda Bosman, Zhiyong Lei, Olivier G. de Jong, Jan J. Molenaar, Enrico Mastrobattista · 2025 · PLoS ONE
43. The Current Landscape of PARP Inhibitors in Ovarian Cancer
    Camille Catherine Gunderson, Britt Kristina Erickson, Megan E. Buechel, Kathleen N. Moore · 2018 · Current Obstetrics and Gynecology Reports
44. Liquid chromatography-tandem mass spectrometry for pharmacokinetics evaluation of AZD5305, a selective PARP1 inhibitor, in mice
    Gi Ju Lee, Jin Woo Kim, Hae-In Choi, Jin‐Young Choi, Kwan Hyung Cho, Tae‐Sung Koo · 2023 · Journal of Analytical Science & Technology
45. Rates of genetic consultation in high‐grade serous ovarian cancer patients in the era of PARP inhibitor therapy: A population‐based study
    Shannon E. Brent, Jacob McGee, Danielle Vicus, Raymond H. Kim, Andrea F. Eisen, Andrew S. Wilton, Lilian Tran Gien · 2024 · International Journal of Gynecology & Obstetrics
46. Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer
    Felix Oladele Okunlola, Fisayo Andrew Olotu, Mahmoud E. S. Soliman · 2021 · Journal of Biomolecular Structure and Dynamics
47. Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?
    Thomas Lee Sutton, Aaron J. Grossberg, Frederick S. Ey, Eileen Mary O'Reilly, Brett C. Sheppard · 2021 · Cancer Biology & Therapy
48. Patient-derived organoids and mini-PDX for predicting METN375S-mutated lung cancer patient clinical therapeutic response
    Ming Jiang, Rongfu Tu, Yiwen Pan, Yuxin Cui, Xin Qi, Hongyu Qin, Lijuan Liu, Xiaorui Wang, Ying Xue, Yao Xu et al. · 2024 · Heliyon
49. Poly (ADP-ribose) polymerase inhibitor sensitized DNA damage caused by an alkylating pyrrole-imidazole polyamide targeting MYCN in neuroblastoma cells
    Xiaoyi Lai, Hiroyuki Yoda, Yuming Qiao, Yuki Kida, Keizo Takenaga, Yoshinao Shinozaki, Nobuko Koshikawa, Atsushi Takatori · 2024 · Biochemical and Biophysical Research Communications
50. Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
    Doreen Grzelak · 2021 · Journal of the Advanced Practitioner in Oncology
51. Genetic variations affecting response of radiotherapy
    Eun Kyung Choi · 2022 · Journal of genetic medicine
52. Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer
    Michael Friedrich · 2022 · IntechOpen eBooks
53. Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
    Palanisamy Sivanandy, Suresh Shanmugham, Rui Ying Lau, Jonathan Yvong Syen Chin, Xiao Xiang Lee, Yun Yun Lau, Wai Ching Lee, Iqbal Danial Said, Jing Ying Lee, Karthikayini Krishnasamy · 2020 · Journal of Pharmacy and Nutrition Sciences
54. Influence of Residual Disease on the Efficacy of PARP Inhibitors in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta Analysis
    Sekyoung Hwang, Ji Hyun Kim, Uisuk Kim, Hyeong In Ha, S.-Y. Park, Myong Cheol Lim · 2025 · Cancers
55. Elucidating the mechanisms of aristolochic acid-induced upper tract urothelial carcinoma: A multi-omics approach combining bioinformatics and computational modeling
    Tongpeng Liu, Yu Yao, Yuan Xu, Haojun Zhang, Lijiang Sun, Guiming Zhang · 2026 · Computational Biology and Chemistry
56. Hereditary Endometrial and Ovarian Cancers
    Garima Yadav, Anshuja Singla · 2019 · Springer eBooks
57. Routine Genetic Testing of Germline Breast Cancer Susceptibility ─ Challenges and Opportunities
    Cornelia Leo, Kathrin Schwedler, Rosaria Condorelli, Nicole Bürki, Jens Huober, Khalil Zaman, Christian Kurzeder, Marcus Hermann Friedrich Vetter · 2023 · healthbook TIMES Oncology Hematology
58. Genomic profiling of relapsed small cell lung cancer reveals potential pathways of therapeutic targets
    Wen Ouyang, Jing Yu, Zihang Zeng, Jun Gong, Junhong Zhang, Conghua Xie · 2023 · Journal of Thoracic Disease
59. Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
    Palanisamy Sivanandy, Suresh Shanmugam, Rui Ying Lau, Jonathan Yvong Syen Chin, Xiao Xiang Lee, Yun Yun Lau, Wai Ching Lee, Iqbal Danial Said, Jing Ying Lee, Karthikayini Krishnasamy · 2020 · Journal of Pharmacy and Nutrition Sciences
60. The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
    Jae Young Joung, Sung Han Kim · 2022 · Journal of Urologic Oncology
61. PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
    Nicola Di Santo, Greta Bagnolini, Yin Wong, Marco Carnelli, Luigi Frigerio · 2022 · IntechOpen eBooks
62. PARP Inhibitors in Breast Cancer: Latest Evidence
    Ryan M. Ponec, Parvin F. Peddi, Rena Desai Callahan · 2017 · Current Breast Cancer Reports
63. DNA Mismatch Repair in Advanced Metastatic Prostate Carcinoma: Clinical Perspective
    Anju Bansal · 2017 · Journal of Cancer Prevention & Current Research
64. Molecular Targeted Therapy for Epithelial Ovarian Cancer
    Hironori Tashiro, Hidetaka Katabuchi · 2018 · Springer eBooks
65. Biological Modulation of Parp Inhibition in Triple Negative Breast Cancer, a Combinational Approach Implementing Multitargeted Epigenetic Therapy (Mtet) with Parp Inhibition, in Advanced Breast Cancer: A Case Study
    Mohammad Amin Nezami, Steve Hager, Julie Taguchi · 2018 · Journal of Cancer Therapy
66. Olaparib: A Tale of Two Dosage Forms
    Trevor N. Christ · 2018 · Cancer therapy & Oncology International Journal
67. Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro
    Nathan E. Stone, Sierra A. Jaramillo, Ashley N. Jones, Adam J. Vazquez, Madison Martz, Lora M. Versluis, Marlee O. Raniere, Haley E. Nunnally, Katherine E. Zarn, Roxanne D. Nottingham et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
68. The effect of nucleic acid-binding ligands on CTG/CAG repeat DNA metabolism in vitro
    Karen Chiang · 2018 · TSpace (University of Toronto)
69. Prevalence of tumor genomic alternations in homologous recombination genes among Taiwanese breast cancers
    Chi‐Cheng Huang, Chun‐Yu Liu, Yi‐Fang Tsai, Pei‐Ju Lien, Yen‐Shu Lin, Ta‐Chung Chao, Chin-Jung Feng, Yen-Jen Chen, Jiun‐I Lai, Nam Nhut Phan et al. · 2021 · Research Square
70. mSWI/SNF interacts with the ribosome and its inhibition/mutations alter translation and sensitize to mTOR/PI3K inhibitors
    Lívia Uličná, Samuel C. Kimmey, Christopher M. Weber, Grace M. Allard, Sean C. Bedall, Gerald R. Crabtree, Gregory R. Bean, Capucine Van Rechem · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
71. Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis
    Alia Ghoneum, Amal Tazzite, Khalid El Bairi, Neveen A. Said · 2021 · Springer eBooks
72. A Deep Learning solution for triaging patient with cancer from their predicted mutational status using histopathological images
    Louis-Oscar Morel, Valentin Dérangère, Laurent Arnould, Sylvain Ladoire, Nathan Vinçon · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
73. DNA Damage Response: A Therapeutic Landscape For Breast Cancer Treatment
    Deepika Singh, Chandra Bhushan Prasad · 2022 · BENTHAM SCIENCE PUBLISHERS eBooks
74. Applications for open access normalized synthesis in metastatic prostate cancer trials
    Thomas H. Luechtefeld, Thomas Bozada, Rahul Goel, Lin Wang, Channing Judith Paller · 2022 · Frontiers in Artificial Intelligence
75. Data from The Interaction of SWI/SNF with the Ribosome Regulates Translation and Confers Sensitivity to Translation Pathway Inhibitors in Cancers with Complex Perturbations
    Lívia Uličná, Samuel C. Kimmey, Christopher M. Weber, Grace M. Allard, Aihui Wang, Nam Q. Bui, Sean C. Bendall, Gerald R. Crabtree, Gregory R. Bean, Capucine Van Rechem · 2023
76. Data from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
    Xiaohua Wu, Jianqing Zhu, Jing Wang, Zhongqiu Lin, Rutie Yin, Wei Sun, Qi Zhou, Songling Zhang, Danbo Wang, Hong Shi et al. · 2023
77. Data from Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
    Xiaohua Wu, Jianqing Zhu, Jing Wang, Zhongqiu Lin, Rutie Yin, Wei Sun, Qi Zhou, Songling Zhang, Danbo Wang, Hong Shi et al. · 2023
78. Drugs that modulate resistance to antitumor agents
    Carmen Avendaño, José Carlos Menéndez · 2023 · Elsevier eBooks
79. Transcriptional Mechanisms of Radioresistance and Therapeutic Implications
    Daniel Y. Kim, Jimmy A. Guo, Daniel Yan Zhao, Errol James Philip, Yun R. Li · 2020 · Applied Radiation Oncology
80. Potential Therapeutic Targets for Leishmaniasis: Modulating Cytokine Production and ECM Organization
    Kavoos Momeni, ‪Saeid Ghorbian, Ehsan Ahmadpour, Rasoul Sharifi, Fariba Berenji · 2023 · Research Square
81. Onkoloji
    Mahmut Büyükşimşek, Mert Tohumcuoğlu, Ali Murat Sedef, Aykut Bahçeci, Erdinç Nayır, Mesut Yılmaz, Yasemin Bakkal Temi, Ali Ayberk Beşen, Ömer Diker, Melih Şimşek et al. · 2022 · Akademisyen Kitabevi eBooks
82. SART1 modulates poly-(ADP-ribose) chain accumulation and PARP1 chromatin localization
    Samuele Lodovichi, Thales C. Nepomuceno, Nicholas T. Woods, Uwe Rix, John M. Koomen, Achille Pellicioli, Alvaro Galli, Álvaro N.A. Monteiro · 2024 · iScience
83. The genomic analysis of patients with musculoskeletal metastases from an unknown origin
    Nicholas C. Eastley, Paul Cool, Mariam Jafri, Manoj Raghavan, Jonathan Daniel Stevenson · 2025 · Surgical Oncology
84. Use of Olaparib in the Management of Metastatic Parathyroid Carcinoma With BRCA1 Mutation
    David Woodfield, Trang Nu Huyen Le, Grace Prince, Hyun Jung Lee, Hetal Ravikumar Vachhani, Priyanka Majety · 2025 · JCEM Case Reports
85. Real-World Impact of a BRCA Testing Protocol in Portugal
    Mariana Malheiro, Bruno Silva, João Rosa, Tomás Costa · 2025 · Cureus
86. Prevalence and Clinical Implications of BRCA1 and BRCA2 Mutations in Breast and Ovarian Cancer Among Pakistani Women
    Tahrim Zafar, Zeeshan Asghar, Urooj Liaqat, Saira Zafar, Areeba Ali Khan, Muqadas Naseer · 2025 · Innovative Research in Applied Biological and Chemical Sciences
87. ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 Activation
    Tadashi Abe, Takaaki Masuda, Taro Tobo, Masahiro Hashimoto, Yusuke Nakano, Hideyuki Saito, Takashi Ofuchi, Tomohiko Ikehara, Akinori Tsujimoto, Takafumi Nakano et al. · 2025 · Cancer Science
88. Design and optimization of olaparib nanostructured lipid carriers for breast cancer treatment
    Gizem Rüya Topal, Özgür Eşi̇m, Meral Sarper, Cansel Köse Özkan, Nurgül K. Bakırhan, Esen Bellur Atıcı, Ayhan Savaşer, Yalçın Özkan · 2025 · Therapeutic Delivery
89. Pyrimidine and NAD salvage pathways : unexpected allies in the maintenance of genome stability
    Sandra Cunha Silveira · 2018
90. Olaparib: Analytical methods for the quantification in drug substance, pharmaceutical formulations and biological matrices
    Saddam Husen Rangrej, Deepak Chadar, Sonika Gour, Swati Sahu, Umesh Kumar Patil, Rajeshwar Vishwanath Kshirsagar, Datta Maroti Pawde · 2026 · Journal of Liquid Chromatography & Related Technologies
91. BindingDB Entry 50016954: Glioblastoma: Current Status, Emerging Targets, and Recent Advances.
    BindingDB · 2023 · UC San Diego